# Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)

> **NCT01432483** · — · NO_LONGER_AVAILABLE · sponsor: **Eisai Inc.**

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Denileukin diftitox (ONTAK)

## Key facts

- **NCT ID:** NCT01432483
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2015-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01432483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01432483, "Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01432483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*